Grab your favorite coffee. This is where you’ll find all the substance you require, and more.

Cognivia-Narrow-Hero-1
Insights

The placebo response in drug development. Part 4: Irritable Bowel Disease

As in many other diseases (e.g. pain, osteoarthritis, rheumatoid arthritis, Parkinson’s Disease, etc ), patients participating in clinical trials for IBD treatments may experience a pronounced placebo…

Read More
Insights

Minimizing Evaluation Error in Osteoarthritis Pain

Osteoarthritis trials have relatively a rate of failure due to many factors, including disease heterogeneity, a disconnect between pain improvement and structural improvement, a strong placebo response,…

Read More
Insights

Placebell©™ Predicts Placebo Response in Initial Study in Parkinson’s Disease

Parkinson’s disease (PD) is one of the most common neurodegenerative disorders, as it affects 1-2 per 1000 of the population at any time(1). Although it is primarily…

Read More
Insights

Prediction of placebo response in Osteoarthritis improves estimation of the treatment effect: Impact on drug development

Placebell©™ can be used in OA and similar diseases in which efficacy is characterized using patient-reported outcomes to reduce the interference of the placebo effect and improve…

Read More
Insights

The placebo response – a phenomenon related to the placebo group or to the individual patient?

Historically, interpretation of clinical trials relies on “assay sensitivity”, or the sensitivity to detect clinically meaningful differences between endpoints measured in the group of patients given active…

Read More
Insights

From covariates to confounding factors: the danger of having too many covariates

Clinical trials typically evaluate efficacy of experimental therapies in heterogeneous patient populations, as patient characteristics vary significantly. These patient characteristics might be prognostic factors that ultimately induce…

Read More

Let’s help you with your next trial.

This field is for validation purposes and should be left unchanged.